blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3426688

EP3426688 - SIGLEC NEUTRALIZING ANTIBODIES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  04.09.2020
Database last updated on 11.09.2024
FormerRequest for examination was made
Status updated on  14.12.2018
FormerThe international publication has been made
Status updated on  15.09.2017
Formerunknown
Status updated on  21.03.2017
Most recent event   Tooltip28.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Innate Pharma
117, Avenue de Luminy
13009 Marseille / FR
[2019/03]
Inventor(s)01 / CORNEN, Stéphanie
11 Chemin Vallon de Ruissatel
13011 Marseille / FR
02 / ROSSI, Benjamin
Résidence la Palmeraie Bât C
70 Avenue d'Haifa
13008 Marseille / FR
03 / WAGTMANN, Nicolai
1776 Monument Street
Concord, MA 01742 / US
 [2019/07]
Former [2019/03]01 / CORNEN, Stéphanie
Résidence Valmante Michelet Bat B1
109 Traverse de la Gouffonne
13009 Marseille / FR
02 / ROSSI, Benjamin
Résidence la Palmeraie Bât C
70 Avenue d'Haifa
13008 Marseille / FR
03 / WAGTMANN, Nicolai
16 Avenue Joseph Liautaud
13260 Cassis / FR
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[N/P]
Former [2019/03]Völlmy, Lukas
Innate Pharma
IP Department
117, avenue de Luminy
13009 Marseille / FR
Application number, filing date17709646.807.03.2017
[2019/03]
WO2017EP55364
Priority number, dateUS201662304957P08.03.2016         Original published format: US 201662304957 P
[2019/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017153433
Date:14.09.2017
Language:EN
[2017/37]
Type: A1 Application with search report 
No.:EP3426688
Date:16.01.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 14.09.2017 takes the place of the publication of the European patent application.
[2019/03]
Search report(s)International search report - published on:EP14.09.2017
ClassificationIPC:C07K16/28
[2019/03]
CPC:
C07K16/2803 (EP,KR,US); A61K47/6801 (US); A61P35/00 (EP,US);
C12N5/12 (US); G01N33/574 (KR); G01N33/57484 (US);
C07K2317/33 (EP,KR,US); C07K2317/34 (EP,KR,US); C07K2317/55 (EP,US);
C07K2317/70 (EP,KR,US); C07K2317/76 (EP,KR,US); C07K2317/92 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/03]
Extension statesBA08.10.2018
ME08.10.2018
TitleGerman:SIGLEC-NEUTRALISIERENDE ANTIKÖRPER[2019/03]
English:SIGLEC NEUTRALIZING ANTIBODIES[2019/03]
French:ANTICORPS NEUTRALISANT LES SIGLECS[2019/03]
Entry into regional phase08.10.2018National basic fee paid 
08.10.2018Designation fee(s) paid 
08.10.2018Examination fee paid 
Examination procedure08.10.2018Amendment by applicant (claims and/or description)
08.10.2018Examination requested  [2019/03]
08.10.2018Date on which the examining division has become responsible
04.09.2020Despatch of a communication from the examining division (Time limit: M06)
08.04.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.06.2021Reply to a communication from the examining division
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
10.06.2021Request for further processing filed
10.06.2021Full payment received (date of receipt of payment)
Request granted
29.06.2021Decision despatched
Fees paidRenewal fee
08.10.2018Renewal fee patent year 03
27.03.2020Renewal fee patent year 04
29.03.2021Renewal fee patent year 05
28.03.2022Renewal fee patent year 06
27.03.2023Renewal fee patent year 07
27.03.2024Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2007049044  (UNIV DUNDEE [GB], et al) [X] 23,31 * page 21, line 5 - line 8 * * page 35, line 19 - line 22 * * page 30, line 7 - page 31, line 15 * * page 17, line 23 * * page 19, line 10 - line 13 *;
 [XI]  - CAMILLA JANDUS ET AL, "Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance", JOURNAL OF CLINICAL INVESTIGATION, US, (20140224), vol. 124, no. 4, doi:10.1172/JCI65899, ISSN 0021-9738, pages 1810 - 1820, XP055342636 [X] 1,5-13,15-24,29,30,33,34,40,41,48-51 * page 1811, column r, paragraph 4 * * figures 3A-3B * * page 1813, column l * [I] 25,27,28,32,35-39,42-44,46

DOI:   http://dx.doi.org/10.1172/JCI65899
 [X]  - JASON E HUDAK ET AL, "Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion", NATURE CHEMICAL BIOLOGY, Basingstoke, (20131124), vol. 10, no. 1, doi:10.1038/nchembio.1388, ISSN 1552-4450, pages 69 - 75, XP055312199 [X] 1,5-13,15-24,29,30,33,34,40,41,48-51 * page 71, column r, paragraph 2 * * figure 3 * * online methods: "reagents and antibodies" *

DOI:   http://dx.doi.org/10.1038/nchembio.1388
 [X]  - Aaron F Carlin ET AL, "PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response", Blood, doi:10.1182/blood-2008-11-, (20090101), pages 3333 - 3336, URL: http://www.bloodjournal.org/content/113/14/3333.full.pdf, (20170512), XP055372312 [X] 1,5-13,15-24,29,30,33,34,40,41,48-51 * page 3335, column l, paragraph 1 * * figure 1 *

DOI:   http://dx.doi.org/10.1182/blood-2008-11-
 [XI]  - HEINZ LÄUBLI ET AL, "Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, US, (20140915), vol. 111, no. 39, doi:10.1073/pnas.1409580111, ISSN 0027-8424, pages 14211 - 14216, XP055372314 [X] 1,5-13,15-24,29,30,33,34,40-44,48-51 * page 14212, column r, paragraph 3 * [I] 25,27,28,32,35-39,42-44,46

DOI:   http://dx.doi.org/10.1073/pnas.1409580111
 [A]  - C Jandus ET AL, "Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance- Supplemental figures", The Journal of Clinical Investigation, (20140401), pages 1 - 14, URL: https://dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf, (20170511), XP055371656 [A] 1,5-13,15-25,27-44,46,48-51 * figure 7A *
 [A]  - JASON E HUDAK ET AL, "Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion-Supplementary information", NATURE CHEMICAL BIOLOGY, Basingstoke, (20131124), vol. 10, no. 1, doi:10.1038/nchembio.1388, ISSN 1552-4450, pages S1 - S21, XP055372305 [A] 1,5-13,15-25,27-44,46,48-51 * "reagents and antibodies" *

DOI:   http://dx.doi.org/10.1038/nchembio.1388
 [A]  - Heinz Läubli ET AL, "Supplementary Information Läubli et al, Engagement of Myelomonocytic Siglecs by Tumor-associated Ligands Modulates the Innate Immune Response to Cancer", (20140930), pages 1 - 22, URL: http://www.pnas.org/content/suppl/2014/09/15/1409580111.DCSupplemental/pnas.1409580111.sapp.pdf, (20170512), XP055372364 [A] 1,5-13,15-25,27-44,46,48-51 * figures S1, S6, S10 * * page 3, paragraph 3 *
 [A]  - STEPHAN VON GUNTEN ET AL, "Basic and Clinical Immunology of Siglecs", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, US, (20081101), vol. 1143, no. 1, doi:10.1196/annals.1443.011, ISSN 0077-8923, pages 61 - 82, XP055372327 [A] 1,5-13,15-25,27-44,46,48-51 * page 72, column r, paragraph 2 - page 73, column r, paragraph 3 * * figure 3 *

DOI:   http://dx.doi.org/10.1196/annals.1443.011
by applicantUS4816567
 US5229275
 US5567610
 US5660827
 US6162963
 WO03101485
 US6737056
 WO2006121168
 WO2007005874
 WO2008156712
 WO2009014708
 EP1238282
 WO2009101611
 WO2009114335
 WO2010077634
 WO2011066501
 WO2011066389
 WO2012065950
 WO2012145493
 US2013034559
 WO2013019906
 WO2015085847
    - SIG792 PCT_ST25 TXT
    - LANIER, ANNUAL REVIEW OF IMMUNOLOGY, (2005), vol. 23, pages 225 - 74
    - WAGTMANN ET AL., IMMUNITY, (1995), vol. 5, pages 439 - 449
    - ANGATA ET AL., J BIOL CHEM, (2000), vol. 275, pages 22127 - 22135
    - ZHANG ET AL., J. BIOL. CHEM., (2000), vol. 275, no. 29, pages 22121 - 22126
    - LAUBLI ET AL., PROC. NAT. ACAD. SCI. USA, (2014), vol. 111, no. 39, pages 14211 - 14216
    - CARLIN ET AL., BLOOD, (2009), vol. 113, pages 3333 - 3336
    - VITALE ET AL., PROC. NAT. ACAD. SCI., (1999), vol. 96, no. 26, pages 15091 - 96
    - FALCO ET AL., J. EXP. MED., (1999), vol. 190, pages 793 - 801
    - HUDAK ET AL., NAT. CHEM. BIOL., (2014), vol. 10, pages 69 - 77
    - JANDUS ET AL., J. CLIN. INVEST., (2014), vol. 124, no. 4, pages 1810 - 18020
    - ANGATA; VARKI, GLYCOBIOLOGY, (2000), vol. 10, no. 4, pages 431 - 438
    - ANGATA; VARKI, J. BIOL. CHEM., (2000), vol. 275, no. 29, pages 22127 - 22135
    - MULLER, METH. ENZYMOL., (1983), vol. 92, pages 589 - 601
    - GREEN ET AL., NATURE GENET, (1994), vol. 7, page 13
    - LONBERG ET AL., NATURE, (1994), vol. 368, page 856
    - TAYLOR ET AL., INT IMMUN, (1994), vol. 6, page 579
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553
    - CHOTHIA; LESK, J. MOL. BIOL, (1987), vol. 196, pages 901 - 917
    - CARILLO ET AL., SIAM J. APPLIED MATH., (1988), vol. 48, page 1073
    - DEVEREUX ET AL., NUCL. ACID. RES., (1984), vol. 12, page 387
    - ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
    - ALTSCHUL ET AL., BLAST Manual, NCB/NLM/NIH
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
    - Antibody Purification Handbook, BIOSCIENCES
    - WARD ET AL., NATURE, (1989), vol. 341, page 544
    - SKERRA ET AL., CURR. OPINION IN IMMUNOL., (1993), vol. 5, page 256
    - PLUCKTHUN, IMMUNOL., (1992), vol. 130, page 151
    - SAUNAL, J. IMMUNOL. METHODS, (1995), vol. 183, pages 33 - 41
    - EHRING H, ANALYTICAL BIOCHEMISTRY, (1999), vol. 267, no. 2, pages 252 - 259
    - ENGEN, J. R.; SMITH, D. L., ANAL. CHEM., (2001), vol. 73, pages 256A - 265A
    - RES FOUND WORKSHOP, (2004), pages 149 - 67
    - HUANG ET AL., JOURNAL OF MOLECULAR BIOLOGY, (1998), vol. 281, no. 1, pages 61 - 67
    - SAITO; PATTERSON, METHODS, (199606), vol. 9, no. 3, pages 516 - 24
    - DOWNARD, J MASS SPECTROM., (200004), vol. 35, no. 4, pages 493 - 503
    - KISELAR; DOWNARD, ANAL CHEM., (19990501), vol. 71, no. 9, pages 1792 - 1801
    - CLACKSON; WELLS, SCIENCE, (1995), vol. 267, pages 383 - 386
    - WELLS, PROC NATL ACAD SCI USA, (1996), vol. 93, pages 1 - 6
    - WANG ET AL., NATURE, (1992), vol. 355, pages 275 - 278
    - FAGERSTAM ET AL., JOURNAL OF MOLECULAR RECOGNITION, (1990), vol. 3, pages 208 - 14
    - NICE ET AL., J. CHROMA-TOGR., (1993), vol. 646, pages 159 - 168
    - LEIPERT ET AL., ANGEW. CHEM. INT. ED., (1998), vol. 37, pages 3308 - 3311
    - KROGER ET AL., BIOSENSORS AND BIOELECTRONICS, (2002), vol. 17, pages 937 - 944
    - SIVORI ET AL., J. EXP. MED., (1997), vol. 186, pages 1129 - 1136
    - VITALE ET AL., J. EXP. MED., (1998), vol. 187, pages 2065 - 2072
    - PESSINO ET AL., J. EXP. MED., (1998), vol. 188, pages 953 - 960
    - NERI ET AL., CLIN. DIAG. LAB. IMMUN., (2001), vol. 8, pages 1131 - 1135
    - PENDE ET AL., J. EXP. MED., (1999), vol. 190, pages 1505 - 1516
    - MORRISON ET AL., PNAS, (1984), page 6851
    - JONES ET AL., NATURE, (1986), vol. 321, page 522
    - REICHMANN ET AL., NATURE, (1988), vol. 332, page 323
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, page 593
    - VERHOEYEN, SCIENCE, vol. 239, page 1534
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CHOTHIA; LESK, J. MOL., (1987), vol. 196, page 901
    - CARTER ET AL., PNAS, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623
    - JAKOBOVITZ ET AL., NATURE, (1993), vol. 362, page 255
    - STROHL, W., CURR. OPIN. BIOTECHNOL., (2009), vol. 20, no. 6, pages 685 - 691
    - BAUDINO ET AL., J. IMMUNOL., (2008), vol. 181, pages 6664 - 69
    - KOHRT ET AL., BLOOD, (2011), vol. 117, no. 8, pages 2423 - 2432
    - BORK ET AL., J PHARM SCI., (200910), vol. 98, no. 10, pages 3499 - 508
    - GLAVEY ET AL., BLOOD, (20140911), vol. 124, no. 11, pages 1765 - 76
    - CHONG ET AL., NATL CANCER INST., (20151107), vol. 108, no. 2
    - ANTONY ET AL., BMC CANCER, (20141202), vol. 14, page 901
    - RILLAHAN ET AL., ACS CHEM BIOL., (20130719), vol. 8, no. 7, pages 1417 - 22
    - ALPHEY ET AL., J. BIOL. CHEM., (2003), vol. 278, no. 5, pages 3372 - 3377
 WO2015EP70550
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.